Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has seen a rise in its stock price by 1.12 in relation to its previous close of 279.60. However, the company has experienced a -3.95% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-17 that CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2023 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) Right Now?
Company’s 36-month beta value is -1.08.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MDGL is 20.08M, and currently, short sellers hold a 19.35% ratio of that floaft. The average trading volume of MDGL on June 19, 2025 was 327.15K shares.
MDGL’s Market Performance
MDGL’s stock has seen a -3.95% decrease for the week, with a -2.75% drop in the past month and a -17.03% fall in the past quarter. The volatility ratio for the week is 2.01%, and the volatility levels for the past 30 days are at 2.38% for Madrigal Pharmaceuticals Inc The simple moving average for the past 20 days is 1.12% for MDGL’s stock, with a -4.22% simple moving average for the past 200 days.
Analysts’ Opinion of MDGL
Many brokerage firms have already submitted their reports for MDGL stocks, with B. Riley Securities repeating the rating for MDGL by listing it as a “Buy.” The predicted price for MDGL in the upcoming period, according to B. Riley Securities is $422 based on the research report published on February 28, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MDGL reach a price target of $405, previously predicting the price at $400. The rating they have provided for MDGL stocks is “Buy” according to the report published on February 27th, 2025.
MDGL Trading at -4.67% from the 50-Day Moving Average
After a stumble in the market that brought MDGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.10% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MDGL starting from CRAVES FRED B, who sale 7,728 shares at the price of $331.84 back on Mar 12 ’25. After this action, CRAVES FRED B now owns 350,076 shares of Madrigal Pharmaceuticals Inc, valued at $2,564,426 using the latest closing price.
CRAVES FRED B, the Director of Madrigal Pharmaceuticals Inc, sale 7,742 shares at $325.25 during a trade that took place back on Mar 13 ’25, which means that CRAVES FRED B is holding 350,076 shares at $2,518,053 based on the most recent closing price.
Stock Fundamentals for MDGL
Current profitability levels for the company are sitting at:
- -1.34 for the present operating margin
- 0.97 for the gross margin
The net margin for Madrigal Pharmaceuticals Inc stands at -1.23. The total capital return value is set at -0.51. Equity return is now at value -50.16, with -37.67 for asset returns.
Based on Madrigal Pharmaceuticals Inc (MDGL), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -3.3. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -30.09.
Currently, EBITDA for the company is -450.12 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 19.58. The receivables turnover for the company is 5.17for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.91.
Conclusion
In a nutshell, Madrigal Pharmaceuticals Inc (MDGL) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
